Jonathan L. Slaughter, MD, MPH
Contact Information
Jonathan L. Slaughter, MD, MPH, is a neonatologist and principal investigator in the Center for Perinatal Research within The Abigail Wexner Research Institute at Nationwide Children's Hospital and an Associate Professor of Pediatrics at The Ohio State University. Dr. Slaughter's ultimate goal is to improve outcomes important to neonatal patients and their families through research that leads directly to improvements in neonatal clinical care. His patient-centered research program focuses on comparative effectiveness research to determine which treatments work best for neonatal patients given specific clinical circumstances and patient characteristics.
-
Neonatology
Physician Team -
Center for Perinatal Research
Principal Investigator -
Neonatology Fellowship
Faculty -
Primary Department
Pediatrics -
Primary Section
Neonatology
- Member, American Academy of Pediatrics
- Member, Society for Pediatric Research
- Member, International Society for Pharmacoepidemiology
Date of Appointment at Nationwide Children’s Hospital: 07/19/2010
Board Certifications
- Neonatal-Perinatal Medicine
- Pediatrics
| Fellowship | Cincinnati Children's Hospital Medical Center | Date Completed: 06/30/2010 |
|---|---|---|
| Residency | Medical University of South Carolina | Date Completed: 06/30/2007 |
| Medical School | Wake Forest University Baptist Medical Center | Date Completed: 05/17/2004 |
| Undergraduate School | Catawba College | Date Completed: 12/31/2000 |
2010 - Present Nationwide Children's Hospital/The Ohio State University, Assistant Professor of Pediatrics
National Heart, Lung, and Blood Institute, United States National Institutes of Health
Comparative Effectiveness of Diuretics and Inhaled Corticosteroids for Bronchopulmonary Dysplasia in Preterm Infants (R03HL140272), Principal Investigator
The goal of this study: To utilize “real-world” data to determine whether diuretic and inhaled corticosteroid treatments for evolving and established BPD reduce mortality and severity of BPD in preterm infants at 36-weeks PMA, as compared to no treatment.
National Heart, Lung, and Blood Institute, United States National Institutes of Health
Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes (R01HL145032), Principal Investigator
The goal of this study: to use a prospective cohort of untreated infants with PDA to predict spontaneous ductal closure timing and to identify clinical risk factors, echo measurements, and biomarkers that are present in the first postnatal month and associated with long-term impairment.